Inquiry Basket
Loading ......
Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to the α4-subunit of human integrins, indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis (MS). As a cornerstone high-efficacy disease-modifying therapy, natalizumab exerts its therapeutic effect by blocking the interaction between α4β1 integrin on lymphocytes and vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells, thereby preventing the migration of immune cells across the blood-brain barrier—a key pathological step in MS disease activity.
Figure 1. Immunogenicity and therapeutic drug level assay for natalizumab treatment.
Unlike small-molecule vasopressin analogues or short synthetic peptides, natalizumab is a high-molecular-weight (~149 kDa) glycoprotein therapeutic whose pharmacokinetics, tissue distribution and immunogenicity are governed by Fc-receptor recycling, neonatal FcRn salvage and HLA-restricted T-cell help in lymphoid tissue. Repeated intravenous exposure to a humanised but non-self antibody framework inevitably triggers humoral immunity in a fraction of patients: published cohorts consistently report that 4–14 % of treated individuals develop persistent anti-natalizumab ADAs, with the majority of these antibodies emerging within the first 6–12 months of treatment. A subset of these ADAs is neutralising — they bind the complementarity-determining regions of the antibody and physically prevent engagement with α4β1 / α4β7 integrins, abolishing the very mechanism on which clinical efficacy depends. The clinical consequences of persistent immunogenicity are well characterised: patients with sustained high-titre ADAs show accelerated clearance of free natalizumab, sub-therapeutic trough concentrations, return of magnetic resonance imaging (MRI) activity, clinical relapse, and infusion-related hypersensitivity reactions. Risk factors for ADA generation include re-exposure after prolonged treatment holidays (>3 months), missed doses, low nadir drug levels, and patient-specific HLA-II haplotypes. The Anti-Natalizumab ELISA Kit provides a matrix-validated bridging immunoassay that selectively captures patient-derived anti-natalizumab immunoglobulins from serum and plasma, delivering both qualitative positivity screening and semi-quantitative antibody titre readout for longitudinal immunogenicity surveillance in clinical and translational research settings.
Under normal immune surveillance, α4β1 (VLA-4) on the surface of circulating lymphocytes binds vascular cell adhesion molecule-1 (VCAM-1) upregulated on inflamed endothelium, while α4β7 binds mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in the gut-associated lymphoid tissue. These two adhesive interactions are the molecular gatekeepers that allow activated leukocytes to extravasate into the central nervous system (CNS) parenchyma and the gut lamina propria. Natalizumab competitively occupies the α4 subunit, blocking both VCAM-1 and MAdCAM-1 engagement and producing three downstream regulatory cascades that are highly specific to integrin biology and absent in small-peptide or complement-targeted therapeutics:
| Kit Name | Core Advantages |
| CNS lymphocyte trafficking cascade | α4β1 blockade prevents the firm adhesion and diapedesis of autoreactive T-cells across the blood–brain barrier, dramatically reducing the number of new gadolinium-enhancing lesions in MS patients. |
| Gut-homing cascade | α4β7 blockade disrupts the recruitment of gut-tropic lymphocytes into the intestinal mucosa, providing symptomatic remission in moderate-to-severe Crohn's disease and refractory ulcerative colitis. |
| Bone-marrow progenitor mobilisation cascade | Natalizumab also transiently elevates circulating CD34+ haematopoietic progenitors and lymphocyte counts, an off-target pharmacodynamic signature that can be quantitatively tracked by pairing free-drug measurement with flow cytometry in research protocols. |
When neutralising ADAs appear, they form high-molecular-weight immune complexes with circulating natalizumab, accelerating reticuloendothelial clearance, shortening the antibody's effective half-life from ~11 days to less than 5 days, and stripping the drug from the α4 binding interface. The net result is a collapse in the free-drug trough concentration and a loss of integrin saturation on the lymphocyte surface. Parallel ELISA quantification of free natalizumab and ADA titres therefore offers a direct, mechanism-linked readout of whether integrin blockade is being maintained — an analytical dimension not provided by routine MRI, JC-virus PCR, or generic IgG assays.
Accurate bioanalytical measurement of circulating natalizumab fractions and treatment-induced anti-natalizumab ADAs constitutes an indispensable pillar of modern MS patient care. Our integrated portfolio delivers regulatory-compliant immunoassay solutions to resolve key analytical challenges including therapeutic drug monitoring, immunogenicity risk assessment, and target-mediated drug disposition.
| Kit Name | Core Advantages | Primary Applicable Scenarios |
| Free Natalizumab ELISA Kit | High selectivity for unbound biologically active natalizumab; resistant to interference from target-mediated drug disposition; wide linear range covering low free drug concentrations in patients with persistent ADAs | Clinical TDM for α4-integrin occupancy assessment; PK/PD modeling of biologically active drug; dose interval optimization for PML risk reduction |
| Anti-Natalizumab ELISA Kit | High sensitivity for low-titer ADA detection; tiered screening and confirmatory assay design; compatible with samples containing residual natalizumab drug interference | Clinical immunogenicity safety evaluation; ADA incidence endpoint analysis for clinical trials; early identification of patients at risk of persistent antibody positivity |
The dual natalizumab ELISA kits are dedicated biologic-monitoring tools for a wide range of preclinical, translational and clinical research workflows, organised into five application pillars that are unique to large-molecule integrin antagonist research:
Accurate bioanalytical measurement of circulating natalizumab and treatment-induced ADAs constitutes an indispensable pillar of modern MS patient care. The integrated portfolio of Free Natalizumab ELISA Kit and Anti-Natalizumab ELISA Kit delivers orthogonal, regulatory-compliant immunoassay solutions to resolve key analytical challenges including variable drug target occupancy, clinical immunogenicity risk assessment, and personalized dose interval optimization. When deployed as a coordinated testing panel, these ELISA platforms enable comprehensive correlation between systemic drug exposure, biologically active free natalizumab levels, and ADA immunogenicity signals, unlocking critical insights into natalizumab pharmacokinetic-pharmacodynamic relationships. For clinical laboratories and researchers, this complete natalizumab ELISA assay suite provides a robust standardized analytical toolset to optimize patient therapeutic outcomes and satisfy regulatory expectations for therapeutic monoclonal antibody monitoring and immunogenicity safety evaluation.
| Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Method | |
| DEIA-JY25244 | Anti-Natalizumab ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
| DEIA-JY25269 | Free Natalizumab ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
Loading ......
